Datco A, Duysens C, Massagé P, Carlier A
Service de Chirurgie de la Main et des Nerfs Périphériques, CHU de Liège, Belgique.
Rev Med Liege. 2013 Mar;68(3):122-7.
Confronted with increasing problems of financing in health care, some question the relevance of certain interventions of high technicality. Today, the limiting factor for practitioners is not any longer situated at the technical and technological level (the survival of macro replantations is assured in 85-90%) but moves slowly and surely towards the economic level. It is true that medicine has a price and that if a technique is expensive, it should at least be justified at the human level and superior to other less expensive therapeutic options which are available. In this article, we will first focus on the long-term outcome of patients and also on the functional benefit which brings them replantation compared to patients who underwent a regularization of their stump and possibly a reconstruction enabling them to be correctly fitted with a prosthesis.
面对日益严重的医疗保健融资问题，一些人质疑某些高技术含量干预措施的相关性。如今，从业者面临的限制因素不再处于技术和工艺层面（宏观再植手术的成功率已确保在85%至90%），而是稳步地转向经济层面。诚然，医疗是有成本的，如果一项技术价格昂贵，那么它至少应该在人文层面具有合理性，并且优于其他现有的成本较低的治疗选择。在本文中，我们将首先关注患者的长期预后，以及与那些接受了残端规范化处理并可能进行了重建以便能够正确佩戴假肢的患者相比，再植手术给患者带来的功能益处。
